In the Pacific region, limited pharmacy competition and distribution costs can affect medication pricing. Zepbound® (Tirzepatide, Injectable pen) by Eli Lilly has been FDA-approved since 2023 for Chronic weight management. Weight Method offers a separate option for Orinda residents: licensed California providers evaluate eligible patients via telehealth and prescribe compounded Tirzepatide, dispensed by a U.S.-licensed 503A pharmacy. Compounded Tirzepatide is not FDA-approved. The Weight Method program is priced at $329/month — same pricing regardless of location.
FDA-approved Zepbound prescribed by licensed providers. Delivered to your door.
Free consultation · No commitment · Results in weeks
From 2,000+ patients · Orinda is already seeing results
Zepbound in Orinda, CA: an FDA-approved GLP-1 medication shown to achieve 15-22% body weight loss in clinical trials. Weight Method offers Zepbound to patients in Orinda from $329/month with virtual consultations and direct-to-door shipping.
Tirzepatide targets the biological mechanisms involved in sustained weight regulation. By activating GLP-1 receptors in the brain, it can reduce hunger signals and slow gastric emptying. Eli Lilly developed Zepbound® as the FDA-approved Injectable pen product, taken Once weekly, approved in 2023. Weight Method is a separate program: licensed providers in California evaluate eligible patients via telehealth and prescribe compounded Tirzepatide, dispensed by a U.S.-licensed 503A pharmacy. Compounded Tirzepatide is not FDA-approved. The Weight Method program for eligible Orinda, CA residents starts at $329/month.
Orinda's suburban communities are hearing more about GLP-1 treatments through word of mouth and national media. Zepbound® is the FDA-approved Injectable pen Tirzepatide product manufactured by Eli Lilly since 2023. Weight Method's separate program is straightforward: an online assessment, a virtual provider consultation, and compounded Tirzepatide delivered to your Orinda address at $329/month. Compounded Tirzepatide is dispensed by a U.S.-licensed 503A pharmacy and is not FDA-approved.
Compounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.

Compounded semaglutide. Once-weekly subcutaneous injection.

Compounded tirzepatide. Dual-action GLP-1/GIP, once-weekly subcutaneous injection.
Consult with a licensed provider in California and start Zepbound from $329/month.
Get Started NowFree consultation. No commitment.